Izba 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
IA/0015 
C.I.z - Changes (Safety/Efficacy) of Human and 
21/09/2021 
Veterinary Medicinal Products - Other variation 
amended 
on 
SmPC, Annex 
II, Labelling 
and PL 
WS/1944 
This was an application for a variation following a 
26/11/2020 
n/a 
worksharing procedure according to Article 20 of 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Commission Regulation (EC) No 1234/2008. 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IAIN/0013/G 
This was an application for a group of variations. 
31/03/2020 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
PSUSA/3011/
Periodic Safety Update EU Single assessment - 
31/10/2019 
n/a 
PRAC Recommendation - maintenance 
201902 
travoprost 
R/0011 
Renewal of the marketing authorisation. 
20/09/2018 
14/11/2018 
SmPC and PL 
Based on the review of data on quality, safety and efficacy, 
the CHMP considered that the benefit-risk balance of Izba 
in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
WS/1385 
This was an application for a variation following a 
26/07/2018 
14/11/2018 
SmPC 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
Page 2/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T/0010 
Transfer of Marketing Authorisation 
16/04/2018 
08/05/2018 
SmPC, 
Labelling and 
PL 
II/0008 
Update of sections 4.4 and 4.8 of the SmPC in order 
15/02/2018 
08/05/2018 
SmPC and PL 
Section 4.4 of SmPC has been updated to include 
to update the safety information in line with 
Travoprost 40 μg/mL Eye Drops PI, based on the 
review of clinical trial and post-marketing data along 
with literature references. 
The package leaflet section 4 is updated accordingly. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
information that IZBA should be used with caution in 
patients with active intraocular inflammation and that 
macular oedema has been reported during treatment with 
prostaglandin F2a analogues. The updates have been done 
in line with the Travoprost 40 μg/mL SmPC. 
Izba SmPC contains in section 4.8 two different tables of 
adverse reactions: Table 1 contains the tabulated list for 
Travoprost 30 µg/mL eye drops and a second table, table 
2, contains the tabulated list of adverse reactions assessed 
to be related with Travoprost 40 µg/mL eye drops, solution.  
Table 2 that includes ADR for Travoprost 40 µg/mL eye 
drops, solution have been updated in line with Travatan 
SmPC: 
Four new adverse events based on post-marketing data: 
insomnia, arrhythmia, epistaxis and vomiting with 
frequency unknown have been added. In addition, table 2 
has been updated following review of clinical trials data as 
follows: cough frequency has been upgraded from rare to 
uncommon and arthralgia frequency has been upgraded 
from not known to rare; dizziness, asthenopia, dyspnoea, 
asthma, visual field defect have been downgraded to 
frequency rare; and four adverse reactions were included: 
trichiasis, eyelash hyperpigmentation (recoded from 
eyelash discoloration, frequency downgraded), rhinitis 
allergic, nasal dryness (based on several nasal disorders 
already listed) and ophthalmic herpes simplex (recoded 
from the combination with herpes simplex and keratitis 
Page 3/5 
 
 
 
 
 
 
 
 
 
II/0005 
Extension of Indication to include treatment of 
18/05/2017 
23/06/2017 
SmPC and PL 
Please refer to Scientific Discussion Izba-H-2738-II-005 
herpetic).  
For further details see the Annexes. 
The Patient Information Leaflet has been updated 
accordingly. 
paediatric patients aged 3 years to < 18 years with 
ocular hypertension or paediatric glaucoma in order 
to decrease of elevated intraocular pressure. 
C.I.6.a - Change(s) to therapeutic indication(s) - 
Addition of a new therapeutic indication or 
modification of an approved one 
T/0007 
Transfer of Marketing Authorisation 
06/04/2017 
20/04/2017 
SmPC, 
Labelling and 
PL 
IB/0006/G 
This was an application for a group of variations. 
03/03/2017 
n/a 
B.II.e.2.z - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Other variation 
B.II.e.6.b - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
PSUSA/3011/
Periodic Safety Update EU Single assessment - 
29/09/2016 
n/a 
PRAC Recommendation - maintenance 
201602 
travoprost 
PSUSA/3011/
Periodic Safety Update EU Single assessment - 
08/10/2015 
n/a 
PRAC Recommendation - maintenance 
Page 4/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
201502 
travoprost 
PSUSA/3011/
Periodic Safety Update EU Single assessment - 
09/10/2014 
n/a 
PRAC Recommendation - maintenance 
201402 
travoprost 
IG/0452 
C.I.8.a - Introduction of or changes to a summary of 
28/07/2014 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
Page 5/5 
 
 
 
 
 
 
 
 
 
 
 
 
